(Q47820029)

5 February 2018

editorial

0 references

review article

1 reference

title

Engineering therapeutic monoclonal antibodies (English)

1 reference

5 February 2018

1 reference

1 reference

3

Ellen S Vitetta

1 reference

5 February 2018

Laurentiu Pop

series ordinal

2

object named as

Laurentiu M Pop

1 reference

5 February 2018

author name string

Xiao-yun Liu

series ordinal

1

1 reference

5 February 2018

publication date

1 April 2008

1 reference

5 February 2018

published in

Immunological Reviews

1 reference

5 February 2018

volume

222

1 reference

5 February 2018

page(s)

9-27

1 reference

5 February 2018

Monoclonal Antibodies Defining Distinctive Human T Cell Surface Antigens

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Reshaping human antibodies for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Mechanisms of killing by anti-CD20 monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Humanization of an anti-p185HER2 antibody for human cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Panitumumab the first fully human monoclonal antibody: from the bench to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

A unique cell surface antigen identifying lymphoid malignancies of B cell origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Immunology. Considering therapeutic antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Signaling antibodies in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Production and characterization of monoclonal antibodies against insulin-like growth factor type 1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

FcR gamma chain deletion results in pleiotrophic effector cell defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Complement activation determines the therapeutic activity of rituximab in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

BCL1, a Murine Model for Chronic Lymphocytic Leukemia: Use of the Surface Immunoglobulin Idiotype for the Detection and Treatment of Tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

The role of idiotype vaccines in the treatment of human B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Anti-idiotype antibodies in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

The evaluation of recombinant, chimeric, tetravalent antihuman CD22 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Immunogenicity of engineered antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Potent antibody therapeutics by design

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Isolation of anti-CD22 Fv with high affinity by Fv display on human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

A label-free immunosensor array using single-chain antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Biodistribution and planar gamma camera imaging of (123)I- and (131)I-labeled F(ab')(2) and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

A fold-back single-chain diabody format enhances the bioactivity of an anti-monkey CD3 recombinant diphtheria toxin-based immunotoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Screening phage display libraries for organ-specific vascular immunotargeting in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Expression of single-chain Fv-Fc fusions in Pichia pastoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

FcgammaRI-deficient mice show multiple alterations to inflammatory and immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Divergent immunoglobulin g subclass activity through selective Fc receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Localization of the binding site for the human high-affinity Fc receptor on IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Molecular basis for immune complex recognition: a comparison of Fc-receptor structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

The structure of a human type III Fcgamma receptor in complex with Fc

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Functional regulation of human neutrophil Fc gamma receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Engineered antibody Fc variants with enhanced effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Effector functions of a monoclonal aglycosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human monocyte Fc receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Physiology and pathophysiology of complement: progress and trends.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Mannose-binding protein recognizes glioma cells: in vitro analysis of complement activation on glioma cells via the lectin pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

A novel protein that participates in nonself discrimination of malignant cells by homologous complement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Antitumor activity of mannan-binding protein in vivo as revealed by a virus expression system: mannan-binding proteindependent cell-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

The membrane attack complex of complement. Assembly, structure and cytotoxic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Engineered antibodies with increased activity to recruit complement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Modulation of the effector functions of a human IgG1 through engineering of its hinge region

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Tumor-specific inhibition of membrane-bound complement regulatory protein Crry with bispecific monoclonal antibodies prevents tumor outgrowth in a rat colorectal cancer lung metastases model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Crystal structure of the complex of rat neonatal Fc receptor with Fc

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

The class I major histocompatibility complex related Fc receptor shows pH-dependent stability differences correlating with immunoglobulin binding and release

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Investigation of the interaction between the class I MHC-related Fc receptor and its immunoglobulin G ligand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

A novel monoclonal antibody design for radioimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Increasing the serum persistence of an IgG fragment by random mutagenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Engineered human IgG antibodies with longer serum half-lives in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

An engineered human IgG1 antibody with longer serum half-life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Multiple roles for the major histocompatibility complex class I- related receptor FcRn

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

In Vivo Pharmacodynamic Effects of Hu1D10 (Remitogen), a Humanized Antibody Reactive Against a Polymorphic Determinant of HLA-DR Expressed on B Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

Production of functional chimaeric mouse/human antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-065X.2008.00601.X

10.1111/J.1600-065X.2008.00601.X

21 January 2018

Identifiers

DOI

1 reference

5 February 2018

1 reference

5 February 2018